Program
polyethylene glycol 3350
Also written as “NER1006”, “polyethyleneglycol3350” and “HalfLytely”.
Its studies are mostly in Constipation · Colonic Neoplasms · Opioid-Induced Constipation · Colorectal Neoplasms · Enterocolitis, Pseudomembranous, led by 4 companies.
Drug pagePolyethylene glycol 3350: every studyAll 64 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sebela Pharmaceuticalsits history only | 100 open or running | phase 4since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Bayer | 30 open or running | phase 4since Oct 9, 2008 | Oct 9, 2008 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Jun 21, 2012 | Jun 21, 2012 | none ahead |
| Taejoon Pharmaceuticalits history only | 10 open or running | phase 3since Apr 21, 2023 | Apr 21, 2023 | none ahead |
Also a collaborator on its studies: Parexel, Quotient Sciences and Pierrel Research Europe.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bayer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 9, 2008First study: phase 4 study in ConstipationFirst studyNCT00770432 · 203 enrolled
- Sep 29, 2010Phase 2 study in ConstipationNCT01212445 · 154 enrolled · Ireland
- Nov 12, 2014Phase 3 study in ConstipationNCT02292459
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Bayer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02292459Constipation | 3 | Withdrawn | Dec 2015 | 0 |
| NCT01212445Constipation · Ireland | 2 | Completed | Nov 2011 | 154 |
| NCT00770432Constipation | 4 | Completed | Jan 2008 | 203 |
How it is read
Names in the registry
- “NER1006”, 9 entries
- “polyethyleneglycol3350”, 5 entries
- “HalfLytely”, 3 entries
- “PEG 3350 plus electrolytes”, 2 entries
- “PLENVU®”, 1 entry
Conditions, from the studies’ own filings
- Constipation, 13 studies
- Colonic Neoplasms, 2 studies
- Opioid-Induced Constipation, 1 study
- Colorectal Neoplasms, 1 study
- Enterocolitis, Pseudomembranous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.